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Introduction 
Mycobacterium Bovis, Bacillus 
Calmette-Guérin (BCG) strain, osteomyelitis 
is a rare complication of intravesical BCG 
treatment of bladder cancer.1 It is clinically 
and radiologically indistinguishable from 
Mycobacterium tuberculosis. M. bovis is the 
main cause of tuberculosis in cattle. Human 
infections occur in the setting of animal 
domestication, infected cow's milk products, 
BCG vaccination, or intravesical BCG 
instillation for bladder cancer treatment. 
Approximately 1-2 percent of human 
tuberculosis cases are attributable to M. 
bovis. Among patients diagnosed with 
tuberculosis, the possibility of M. bovis 
should be considered in the setting of 
foreign born individuals, Hispanic ethnicity, 
age less than 15 years, immunosuppression, 
HIV infection, extra pulmonary disease, 
history of intravesical BCG, and non-
responsiveness to standard TB treatment.1 
 
Case Report 
An 80-year-old man was admitted from 
an outside hospital for further work-up of 
low back pain, bilateral lower extremity 
weakness, and gait instability of six-month 
duration. He also reported unintentional 
weight loss of 40 pounds and fatigue over 
past 5-6 months. He had no fever or night 
sweats. He was diagnosed three years earlier 
with bladder cancer and had cystoscopy with 
tumor  removal.  He   subsequently   had   15  
 
 
 
instillations of BCG therapy. At the end of 
BCG therapy, he was declared as being in 
remission from bladder cancer. His other 
past medical history included hypertension 
and supraventricular tachycardia.  
On exam, the patient was lethargic and 
had severe lower extremity weakness. Labs 
showed an erythrocyte sedimentation rate of 
81 mm/hr, C-reactive protein of 11.73 mg/L, 
thrombocytopenia with platelets of 67,000, 
and anemia with hemoglobin of 9.4 gm/dL 
and hematocrit of 28.3%.  
At the outside hospital, computed 
tomography (CT) of the spine showed a T10 
mass (Figures 1 and 2). CT of the chest, 
abdomen, and pelvis did not show any 
abnormality. Positron emission tomography 
showed increased uptake at T10. A CT-
guided needle biopsy showed non-specific 
inflammation and fibrosis but no cancer. 
Due to his worsening lower extremity 
weakness and low back pain, a documented 
spinal mass, and history of bladder cancer, it 
was presumed that patient had a recurrence 
of bladder cancer and he received ten 
radiation therapy treatments to the T10 area. 
The last treatment was a week prior to the 
admission to our hospital. As he did not 
improve with radiation treatment, he was 
referred for spinal surgery at our hospital.  
The patient underwent a T9-T10 thoracic 
laminectomy and decompression with T6-L1 
posterior    fusion    with    associated   tissue 
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biopsy of the T10 vertebral body, which 
showed no evidence of malignancy. After 
surgery, he had some improvement in his 
left extremity weakness.  
The patient was transferred to a long-
term acute care facility to be followed by a 
neurosurgeon. Three weeks later, the acid-
fast bacilli culture of the T10 tissue taken 
from the back surgery was positive for 
mycobacterium bovis. This organism was 
sensitive to isoniazid, ethambutol, and 
rifampin, but resistant to pyrazinamide.  
The patient was readmitted with a 
diagnosis of BCG strain osteomyelitis three 
years after he received BCG treatment for 
his bladder cancer. A chest x-ray was 
without evidence for pulmonary tuber-
culosis. An HIV test was negative. Further 
exploration of spine to look for any residual 
infection and debridement was deferred due 
to moderate malnutrition and poor 
functional status (due to his recent spine 
surgery from which he was still recovering 
and had ongoing weakness).  
The patient’s spine infection was 
managed medically. He was started on 
isoniazid, ethambutol, and rifampin and 
transferred to a long-term acute care facility. 
He completed two months of isoniazid, 
ethambutol, and rifampin followed by seven 
months of isoniazid and rifampin. With 
treatment, his strength and low back pain 
improved and he was discharged home.  
 
Discussion 
BCG is an attenuated derivative of the 
virulent strain of M. bovis. Intravesical 
instillation of BCG was first introduced by 
Morales and associates2 and is an effective 
agent for therapy and prophylaxis of 
superficial transitional cell carcinoma of the 
urinary bladder. It has been used to treat 
existing or residual tumors, prevent tumor 
recurrence, prevent disease progression, and 
prolong survival.3 Common complications 
of BCG immunotherapy include cystitis (up 
to 90%), hematuria (up to 34%), and fever 
(3%).4,5 Severe complications, including 
sepsis and systemic infections, are rare (less 
than 1%). Severe systemic disease also can 
present with disseminated intravascular 
coagulopathy, respiratory failure, jaundice, 
Figure 1. CT scan showing T10 osteo-
myelitis, sagittal plane. 
Figure 2. CT scan showing T10 osteo-
myelitis, transverse plane. 
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and leukopenia.4 Late organ-specific 
manifestations (pneumonitis, hepatitis, 
pyelonephritis, osteomyelitis, and bone 
marrow infection) are due to a reactivation 
of BCG infection. 
Risk factors for complications from 
BCG instillation include traumatic 
catheterization, urethral injury during BCG 
instillation, bladder biopsy, hematuria, 
active infection, immunosuppression, 
bladder outlet obstruction, radiation cystitis, 
and transurethral resection of the prostate 
and deep bladder tumor within two weeks of 
instillation.6-11 BCG organisms have been 
documented in the bladder up to 16.5 
months after completion of BCG 
intravesical instillation therapy.6 Long 
lasting and persistent BCG DNA in the 
bladder wall after intravesical BCG therapy 
may account for long-term immune-
activation and immune anticancer effects, 
and may explain why patients are still at risk 
of disseminated infection for months and 
even years after BCG therapy.  
M. bovis can manifest with primary and 
reactivation forms. Involvement may be 
pulmonary, extra pulmonary, or dissem-
inated and is indistinguishable from 
tuberculosis. The prognosis for disease is 
worse than M. tuberculosis.  
Susceptibility testing of a mycobacterial 
isolate with resistance to pyrazinamide or 
individuals known to have contact with M. 
bovis often leads to identification of M. 
bovis.12 Staining for acid-fast bacilli, PPD 
skin test, mycobacterial culture, and the 
interferon gamma release assay are capable 
of detecting Mycobacterium infections, but 
cannot identify M. bovis versus M. 
tuberculous. Differentiation of M. bovis 
from M. tuberculosis includes colony 
morphology, biochemical assays (M. bovis 
has negative niacin production and negative 
nitrate reduction tests), susceptibility tests 
(e.g., resistance to pyrazinamide), and PCR 
genomic analysis. Based on colony 
morphology, M. bovis BCG strain can be 
distinguished from M. bovis wild strain.  M. 
bovis BCG strains are eugonic and grow 
more rapidly (3-4 weeks to grow on 
Löwenstein-Jensen medium), have a rough, 
buff-colored appearance, and in some cases, 
accumulate niacin. M. bovis wild strains, on 
the other hand, have a very slow growth 
rate, produces dysgonic-appearing colonies 
on Löwenstein-Jensen medium, and 
frequently require 6 to 8 weeks to become 
observable.  
One should consider M. bovis BCG 
strain when a nucleic acid probe is positive, 
but the organism is characterized by 
negative nitrate reduction, negative niacin 
production, susceptibility to inhibition by 
thiophene-2-carboxylic acid hydrazide 
(TCH), and resistance to pyrazinamide, 
especially in a patient with a history of 
intravesical BCG therapy for bladder 
cancer.13 For conclusive identification of M. 
bovis, the isolate should be sent to the state 
public health laboratory or a mycobacteria 
reference laboratory, which was done in our 
case. The duration of therapy for pulmonary 
and extra pulmonary disease should be nine 
months; genetic resistance of M. bovis to 
pyrazinamide precludes use of a short-
course (6-month) regimen. The regimen 
consists of isoniazid, rifampin, and 
ethambutol for the first two months, 
followed by isoniazid and rifampin for seven 
months and for meningitis up to a total of 
twelve months. 
At least fifteen cases of M. bovis BCG 
strain osteomyelitis have been reported 
following intravesical therapy.13-27 The 
range for presentation post instillation varies 
between two weeks and 12 years. In one 
report, 1.5 years after diagnosis and surgical 
and anti-tuberculous treatment, the patient 
was pain-free with no functional limitations 
or clinical and imaging findings of recurrent 
infection.24 Notably, 8 of 15 patients with 
vertebral osteomyelitis required surgical 
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intervention with debridement and spinal 
stabilization similar to our case.13,15,16,19-
21,24,27 One patient received a presumptive 
diagnosis of metastatic lung cancer and 
underwent empiric radiation therapy to the 
back and chest similar to our case. Another 
case developed pancytopenia from bone 
marrow infection with BCG two years after 
intravesical instillation of BCG for bladder 
cancer.22 Mycobacterium bovis osteo-
myelitis involving a hip arthroplasty17 and 
infected aortic aneurysm along with 
vertebral osteomyelitis also has been 
reported.26 
Although the systemic complications are 
known from the use of intravesical BCG, 
osteomyelitis is a rare complication and 
recognition of this syndrome is critical to 
institution of appropriate therapy and 
prevention of long-term complications in 
patients treated with intravesical BCG. 
Timely diagnosis is important, because 
chemotherapy, when initiated early in the 
disease, can preclude the necessity for 
surgical intervention. 
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